Home/Filings/4/0000950170-23-051728
4//SEC Filing

Adjuvant Global Health Technology Fund, L.P. 4

Accession 0000950170-23-051728

CIK 0001880438other

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 7:13 PM ET

Size

17.2 KB

Accession

0000950170-23-051728

Insider Transaction Report

Form 4
Period: 2023-09-29
Transactions
  • Sale

    Common Stock

    2023-10-02$16.07/sh4,770$76,6542,081,573 total
  • Sale

    Common Stock

    2023-09-29$16.28/sh15,764$256,638394,639 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
  • Sale

    Common Stock

    2023-09-29$16.28/sh83,337$1,356,7262,086,343 total
  • Sale

    Common Stock

    2023-10-02$16.07/sh902$14,495393,737 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
Transactions
  • Sale

    Common Stock

    2023-09-29$16.28/sh83,337$1,356,7262,086,343 total
  • Sale

    Common Stock

    2023-10-02$16.07/sh902$14,495393,737 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
  • Sale

    Common Stock

    2023-09-29$16.28/sh15,764$256,638394,639 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
  • Sale

    Common Stock

    2023-10-02$16.07/sh4,770$76,6542,081,573 total
Transactions
  • Sale

    Common Stock

    2023-10-02$16.07/sh902$14,495393,737 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
  • Sale

    Common Stock

    2023-09-29$16.28/sh15,764$256,638394,639 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
  • Sale

    Common Stock

    2023-10-02$16.07/sh4,770$76,6542,081,573 total
  • Sale

    Common Stock

    2023-09-29$16.28/sh83,337$1,356,7262,086,343 total
Transactions
  • Sale

    Common Stock

    2023-09-29$16.28/sh83,337$1,356,7262,086,343 total
  • Sale

    Common Stock

    2023-09-29$16.28/sh15,764$256,638394,639 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
  • Sale

    Common Stock

    2023-10-02$16.07/sh902$14,495393,737 total(indirect: By Adjuvant Global Health Technology Fund DE, L.P.)
  • Sale

    Common Stock

    2023-10-02$16.07/sh4,770$76,6542,081,573 total
Footnotes (5)
  • [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
  • [F4]Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
  • [F5]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Documents

1 file

Issuer

AN2 Therapeutics, Inc.

CIK 0001880438

Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001783165

Filing Metadata

Form type
4
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 7:13 PM ET
Size
17.2 KB